Phosphodiesterase Type 5 Inhibitors and Risk of Malignant Melanoma: Matched Cohort Study Using Primary Care Data from the UK Clinical Practice Research Datalink

Open Access

Peer-reviewed

Research Article

Anthony Matthews,

Affiliation Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯
Sinéad M. Langan,

Affiliation Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯
Ian J. Douglas,

Affiliation Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯
Liam Smeeth,

Affiliation Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯
Krishnan Bhaskaran

* E-mail: krishnan.bhaskaran@lshtm.ac.uk

Affiliation Department of Non-Communicable Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
⨯

Reader Comments (0)

Melanoma
Is the Subject Area "Melanoma" applicable to this article?

Thanks for your feedback.
Cancer risk factors
Is the Subject Area "Cancer risk factors" applicable to this article?

Thanks for your feedback.
Overexposure to sun
Is the Subject Area "Overexposure to sun" applicable to this article?

Thanks for your feedback.
Basal cell carcinomas
Is the Subject Area "Basal cell carcinomas" applicable to this article?

Thanks for your feedback.
Colorectal cancer
Is the Subject Area "Colorectal cancer" applicable to this article?

Thanks for your feedback.
Diabetes mellitus
Is the Subject Area "Diabetes mellitus" applicable to this article?

Thanks for your feedback.
Primary care
Is the Subject Area "Primary care" applicable to this article?

Thanks for your feedback.
Cutaneous melanoma
Is the Subject Area "Cutaneous melanoma" applicable to this article?

Thanks for your feedback.